FY2028 Earnings Estimate for WVE Issued By Wedbush

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities researchers at Wedbush issued their FY2028 earnings per share (EPS) estimates for Wave Life Sciences in a note issued to investors on Thursday, May 8th. Wedbush analyst Y. Zhong forecasts that the company will earn ($0.88) per share for the year. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences' FY2029 earnings at ($0.64) EPS.

Other research analysts have also issued reports about the company. HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a "buy" rating and a $26.00 target price on the stock. Cantor Fitzgerald initiated coverage on Wave Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 target price for the company. Finally, StockNews.com lowered shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $21.17.

Wave Life Sciences Price Performance

Shares of WVE stock opened at $6.59 on Monday. The firm has a market cap of $1.02 billion, a PE ratio of -5.94 and a beta of -0.92. The company has a 50-day moving average of $7.78 and a two-hundred day moving average of $11.13. Wave Life Sciences has a 1-year low of $4.25 and a 1-year high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). The business had revenue of $9.18 million for the quarter, compared to analysts' expectations of $11.65 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. During the same quarter in the prior year, the company posted ($0.24) earnings per share.

Hedge Funds Weigh In On Wave Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its holdings in shares of Wave Life Sciences by 63.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock valued at $63,074,000 after purchasing an additional 1,972,262 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Wave Life Sciences in the fourth quarter valued at approximately $20,545,000. Polar Capital Holdings Plc purchased a new stake in Wave Life Sciences in the fourth quarter valued at approximately $12,370,000. MPM Bioimpact LLC boosted its holdings in shares of Wave Life Sciences by 138.5% in the fourth quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock valued at $18,422,000 after acquiring an additional 864,766 shares during the period. Finally, Driehaus Capital Management LLC grew its position in shares of Wave Life Sciences by 14.6% during the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock worth $83,033,000 after acquiring an additional 853,589 shares during the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Wave Life Sciences

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now directly owns 16,115 shares of the company's stock, valued at $157,443.55. This trade represents a 39.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.